We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$239M
Cap. Flow %
-32.31%
Top 10 Hldgs %
67%
Holding
218
New
56
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Healthcare 6.89%
2 Financials 5.45%
3 Technology 3.65%
4 Industrials 1.84%
5 Communication Services 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCON icon
26
Recon Technology
RCON
$39.6M
$3.62M 0.49%
71,117
+19,450
+38% +$1.13M
MRTX
27
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.41M 0.46%
193
– –
ZNB
28
Zeta Network Group
ZNB
$679K
– –
0
– –
BIVI icon
29
BioVie
BIVI
$10M
$3.38M 0.46%
+5,049
New +$5.41M
ATNM icon
30
PUT
Actinium Pharmaceuticals
ATNM
$27.2M
$3.33M 0.45%
+3,757
New +$26.1K
VINC
31
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$3.23M 0.44%
10,000
-3,553
-26% -$1.04M
PMCB icon
32
PharmaCyte Biotech
PMCB
$6.33M
$3.2M 0.43%
+1,010,146
New +$3.55M
NBEV
33
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$3.18M 0.43%
2,288,078
+558,147
+32% +$1.02M
NMTR
34
PUT
DELISTED
9 Meters Biopharma
NMTR
$3.17M 0.43%
1,219
+313
+35% +$7.38K
ANY icon
35
PUT
Sphere 3D
ANY
$16.8M
$3.02M 0.41%
+73
New +$23.4K
GFAI icon
36
Guardforce AI
GFAI
$9.93M
$2.88M 0.39%
+18,191
New +$2.88M
IONS icon
37
Ionis Pharmaceuticals
IONS
$9.14B
$2.84M 0.38%
84,600
+6,600
+8% +$249K
IONS icon
38
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$2.84M 0.38%
846
+5
+0.6% +$188
ZVRA icon
39
PUT
Zevra Therapeutics
ZVRA
$575M
$2.72M 0.37%
2,912
-4,205
-59% -$42.4K
RIOT icon
40
PUT
Riot Platforms
RIOT
$8.03B
$2.62M 0.35%
1,019
– –
LFWD icon
41
ReWalk Robotics
LFWD
$19.6M
$2.46M 0.33%
19,438
+3,144
+19% +$390K
ORIO
42
PUT
Orion Digital Corp
ORIO
$15.6M
$2.38M 0.32%
1,835
-893
-33% -$14.8K
SLAI
43
PUT
DELISTED
SOLAI Ltd ADS
SLAI
$2.34M 0.32%
+41
New +$21.8K
NCTY
44
PUT
The9 Ltd
NCTY
$70.6M
$2.33M 0.31%
226
+57
+34% +$7.17K
MARA icon
45
Marathon Digital Holdings
MARA
$4.34B
$2.29M 0.31%
72,643
+45,053
+163% +$1.46M
TCDA
46
DELISTED
Tricida, Inc. Common Stock
TCDA
$2.2M 0.3%
475,000
+38,500
+9% +$159K
POL
47
PUT
DELISTED
Polished.com Inc.
POL
$2.14M 0.29%
136
+110
+423% +$16.6K
ORMP icon
48
PUT
Oramed Pharmaceuticals
ORMP
$171M
$2.14M 0.29%
972
-446
-31% -$7.6K
AMRN
49
PUT
Amarin Corp
AMRN
$293M
$2.1M 0.28%
206
+37
+22% +$3.64K
OCUL icon
50
PUT
Ocular Therapeutix
OCUL
$1.85B
$2.1M 0.28%
2,097
+539
+35% +$6.05K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $239M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.9% of assets, down from 10% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 56 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.